Novartis investigative site
Nuremberg 90491
2 studies enrolling now · 28 studies all time
What they study most
Acute Heart Failure, Alzheimer Disease, Alzheimer's Disease, Ankylosing Spondylitis, Atherosclerosis, Carcinoma, Non-Small-Cell Lung, Cardiovascular Events, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Chronic Plaque Psoriasis, Cytokine Storm (Covid-19)
Studies at this site
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — Recruiting now
- Phase 2 Study of Rapcabtagene Autoleucel in Myositis — Running, not enrolling
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
- Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
- Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
- Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
- Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients — Completed
- Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis — Completed
- ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
- Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
- Extension in AS: Sustainability of Benefits, Safety and Tolerability — Completed
- Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis — Completed
- Global Non-interventional Heart Failure Disease Registry — Stopped early
- 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis — Completed
- Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy — Stopped early
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
- Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension — Completed
- Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer — Completed
- Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) — Completed
- Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma — Completed
- A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People — Stopped early
- Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed
- Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline — Completed
- Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis — Completed
- Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease — Completed
- Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) — Completed